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The combination of palmitoylethanolamide (PEA), an endogenous fatty acid amide belonging to the fa-
mily of the N-acylethanolamines, and the ﬂavonoid luteolin has been found to exert neuroprotective
activities in a variety of mouse models of neurological disorders, including brain ischemia. Indirect
ﬁndings suggest that the two molecules can reduce the activation of mastocytes in brain ischemia, thus
modulating crucial cells that trigger the inﬂammatory cascade. Though, no evidence exists about a direct
effect of PEA and luteolin on mast cells in experimental models of brain ischemia, either used separately
or in combination. In order to ﬁll this gap, we developed a novel cell-based model of severe brain
ischemia consisting of primary mouse cortical neurons and cloned mast cells derived from mouse fetal
liver (MC/9 cells) subjected to oxygen and glucose deprivation (OGD).
OGD exposure promoted both mast cell degranulation and the release of lactate dehydrogenase (LDH)
in a time-dependent fashion. MC/9 cells exacerbated neuronal damage in neuron-mast cells co-cultures
exposed to OGD. Likewise, the conditioned medium derived from OGD-exposed MC/9 cells induced
signiﬁcant neurotoxicity in control primary neurons. PEA and luteolin pre-treatment synergistically
prevented the OGD-induced degranulation of mast cells and reduced the neurotoxic potential of MC/9
cells conditioned medium. Finally, the association of the two drugs promoted a direct synergistic neu-
roprotection even in pure cortical neurons exposed to OGD.
In summary, our results indicate that mast cells release neurotoxic factors upon OGD-induced acti-
vation. The association PEA-luteolin actively reduces mast cell-mediated neurotoxicity as well as pure
neurons susceptibility to OGD.
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Mast cells (MCs) are bone marrow-derived perivascular re-
sident cells widely distributed throughout virtually all vascular-
ized tissues where they normally reside in proximity to blood
vessels, nerves, smooth muscle cells, mucus-producing glands, and
hair follicles. MCs can be especially numerous in anatomical re-
gions that are directly exposed to the environment such as the
skin, airways, and gastrointestinal tract (Metz et al., 2007). Because
of their peculiar anatomical distribution, MCs act as ﬁrst line of
defense in the immune system against invading pathogens and
environmental antigens and allergens. Initially known mainly for
their pathogenic role in allergic and anaphylactic reactions, it is
nowwell documented MCs involvement in processes of innate and
adaptive immunity and inﬂammation. Mastocytic activation
E. Parrella et al. / Brain Research 1648 (2016) 409–417410occurs upon response to a wide range of physical and chemical
stimuli, including trauma, hypoxia, allergens, toxic substances,
complement factors, endogenous and exogenous peptides, cyto-
kines and other inﬂammatory mediators (Galli et al., 2005). MCs
also are present in the central nervous system (CNS) and they have
been identiﬁed in different mammalian brain regions, including
meninges, choroid plexus, olfactory bulb, mesencephalon, par-
enchima of thalamus and hypothalamus, hippocampus and en-
thorinal cortex (Dropp, 1979; Silver and Curley, 2013; Theoharides,
1990). MCs have been associated with various neuroinﬂammatory
conditions of the CNS, such as stroke, multiple sclerosis, traumatic
brain injury and eventually Alzheimer's Disease (AD) and Parkin-
son's Disease (PD) (Nelissen et al., 2013). A body of evidence points
out the involvement of MCs in the pathophysiology of brain
ischemia (Lindsberg et al., 2010; Strbian et al., 2009). After ische-
mia, MCs translocate from brain perivascular positions and can be
more abundantly found in the ischemic cerebral area where they
release their granules contents and mediators of inﬂammation
(Caltagirone et al., 2015; Hu et al., 2004; Lindsberg et al., 2010;
Silverman et al., 2000; Strbian et al., 2006). In rodent models of
brain ischemia, both genetic deﬁciency or pharmacological in-
hibition of MCs led to a signiﬁcant reduction of ischemic damages,
including brain blood barrier (BBB) disruption, cerebral edema,
and neutrophil inﬁltration (Mattila et al., 2011; Strbian et al.,
2006).
In the light of the above observations, MCs appear as an at-
tractive target for the treatment of brain ischemia. In this study we
tested PEA (palmitoylethanolamide) and luteolin (3′, 4′, 5, 7-tet-
rahydroxyﬂavone), two natural compounds potentially active as
MCs modulators, on cell-based models of brain ischemia.
PEA is an endogenous lipid amide belonging to the family of
the N-acylethanolamines (NAEs). PEA can be found in mammalian
tissues, especially the brain. It has been proposed that PEA may be
produced “on demand” in the CNS during brain injury to coun-
teract neuronal damage (Esposito et al., 2014; Hansen, 2010). PEA
is endowed with anti-inﬂammatory and analgesic properties and
it has been investigated in both cellular and animal models of
chronic pain (De Filippis et al., 2011; LoVerme et al., 2006), AD
(D’Agostino et al., 2012; Scuderi et al., 2014; Scuderi et al., 2012),
PD (Esposito et al., 2012), uveitis (Impellizzeri et al., 2015), diabetic
retinopathy (Paterniti et al., 2015) and stroke (Ahmad et al., 2012;
Garg et al., 2010).
Luteolin is a ﬂavonoid present in many plants, including var-
ious fruits, vegetables and medicinal herbs (Lopez-Lazaro, 2009).
Luteolin and its congeners exhibit anti-inﬂammatory, antioxidant,
neuroprotective and anti-carcinogenic activities (Dajas et al., 2003;
Guerra-Araiza et al., 2013) and have been reported to have a po-
tential for the treatment of autism (Theoharides et al., 2013),
multiple sclerosis (Theoharides, 2009), cancer (Attoub et al., 2011)
and stroke (Qiao et al., 2012; Qiao et al., 2014; Zhao et al., 2011).
Several reports indicate that the two molecules used separately
can reduce MCs activation in a variety of in vitro and in vivo ex-
perimental models (De Filippis et al., 2011; De Filippis et al., 2013;
Esposito et al., 2011; Facci et al., 1995; Jeon et al., 2014; Jin et al.,
2011; Kritas et al., 2013; Skaper et al., 2013, 1996a, 1996b).
Moreover, recent ﬁndings indicate that the combination PEA-
luteolin is effective in reducing inﬂammation in animal models of
spinal cord injury (Paterniti et al., 2013), AD (Paterniti et al., 2014),
traumatic brain injury (TBI) (Cordaro et al., 2015), anxiety/de-
pression (Crupi et al., 2013), arthritis (Impellizzeri et al., 2013), PD
(Siracusa et al., 2015) and brain ischemia (Caltagirone et al., 2015),
and in promoting the maturation of oligodendrocytes precursor
cells in vitro (Barbierato et al., 2015). Finally, it has been recently
shown that the combination PEA-luteolin is able to reduce the
ischemia-induced MCs inﬁltration in a rat model of brain ischemia
(Caltagirone et al., 2015).The aim of this study was to test the efﬁcacy of the combination
PEA-luteolin in reducing neuronal damage in cell-based models of
brain ischemia, with particular focus on the effect of the two
compounds on MCs-mediated neurotoxicity.2. Results
2.1. OGD promotes MC/9 cells activation
We tested the effect of OGD on degranulation and cellular da-
mage of MC/9 cells. Cultured MC/9 cells were exposed to 3, 6, 8, or
16 h of OGD, then harvested and processed. As pointed out by
previous studies on primary rat MCs, OGD induced mastocytic
activation (Hu et al., 2005). When stained with toluidine blue and
observed by light microscopy, most MC/9 cells in the control group
showed metachromatic granules and membrane integrity (Fig. 1A).
OGD exposure resulted in the appearance of numerous MC/9 cells
undergoing degranulation (Fig. 1A). Granule release in MC/9 cells
subjected to OGD was signiﬁcantly higher than control group after
6 h of anoxic insult, and increased further thereafter (Fig. 1B). β-
hexosaminidase release, another marker of mastocytic de-
granulation, increased similarly in a fashion dependent from OGD
duration, becoming signiﬁcantly different than control after 6 h of
OGD exposure (Fig. 1C). Together with the degranulation, OGD
promoted also LDH release, a marker of cellular damage. A sig-
niﬁcant increase was observed after 6 h of anoxic insult, followed
by a progressive growth over time (Fig. 1D).
2.2. OGD-activated MC/9 cells release neurotoxic factors
Next, we investigated whether MC/9 cells could modulate
neuronal damage induced by OGD. Based on our results showing a
signiﬁcant mastocytic activation after 6 h of OGD, in the next ex-
periments we challenged MC/9 cells with 6 h of anoxic condition.
In a ﬁrst experimental approach, we established a cell model of
cerebral ischemia based on a trans-well co-culture system, with
neurons aderent in the well and MC/9 cells seeded in the upper
trans-well (Fig. 2A). This system allowed us to model the inter-
actions between neurons and MCs in pathophysiological condi-
tions of cerebral ischemia. Pure neurons or neurons- MC/9 cells co-
cultures were subjected to 6 h of OGD, followed by 24 h of re-
perfusion, in accordance with the OGD experimental procedure we
developed for neuronal cultures (Lanzillotta et al., 2013, 2010;
Sarnico et al., 2009). Neurons- MC/9 cells co-cultures displayed
higher cell death when compared to pure neurons (Fig. 2B). This
effect is likely due to MC/9 cells-mediated ampliﬁcation of the
neurotoxic response rather than MC/9 cells release of LDH. The
LDH release in sister cultures of MC/9 cells, seeded at the same
density as in the co-cultures, revealed negligible enzyme discharge
in the medium when compared to the LDH released by pure
neuronal cultures (Fig. 2C).
In order to further investigate the adverse effect of MCs on
neurotoxicity, using a second experimental approach, conditioned
medium (CM) from OGD-activated MC/9 cells was added to se-
parate pure neurons. CM from MC/9 cells subjected to 6 h of OGD
was collected at the end of the anoxic event, or after a further
reperfusion period, and transferred to neuronal cultures (Fig. 2D).
The addition of CM harvested from MC/9 cells immediately after
OGD did not induce signiﬁcant toxicity in neurons (Fig. 2E). Con-
versely, the addition of CM collected from MC/9 cells exposed to
OGD followed by 24 h-reperfusion extremely exacerbated the cell
death (Fig. 2E). This result suggests that the release of neurotoxic
factors from MC/9 cells is responsible for the enhanced neuronal
cell death produced by MC/9 cells during co-exposure to OGD.
Fig. 1. OGD promotes MC/9 cells degranulation and LDH release. MC/9 cells were exposed to 3, 6, 8 or 16 h of OGD. At the end of OGD period the cells were processed to
determine their degranulation status or LDH release. (a) Images depicting MC/9 cells stained with acidic toluidine blue in control groups or after 6 h of OGD (light mi-
croscopy, 40 x). (b) Percentage of MC/9 cells degranulation assessed by toluidine blue staining. (c) Mastocytic degranulation assessed by β-hexosaminidase release assay. The
results are expressed as percentage of β-hexosaminidase activity. (d) Percentage of LDH release. Mastocytic degranulation detected with both the assays and LDH release
were signiﬁcant higher in OGD groups after 6 h of anoxic insult and rose further thereafter. Each value is expressed as the mean 7 SEM of 12–14 wells from three-four
independent experiments. **po0.01,***po0.001 vs corresponding control, t-test.
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OGD-dependent activation of MC/9 cells
We evaluated whether PEA and luteolin, tested at concentra-
tion ranges 1 nM to 100 mM, could dampen mastocytic activation
upon OGD treatment. The drugs were added to cell cultures 15 h
before OGD and maintained in the medium during the 6 h of an-
oxic event. Mastocytic degranulation was assessed at the end of
OGD period. PEA did not affect degranulation of MC/9 cells ex-
posed to OGD (Fig. 3A). Pre-treatment of MC/9 cells with luteolin
signiﬁcantly prevented mastocytic degranulation at the con-
centration range 10–100 nM (Fig. 3B). When the two drugs were
added together at ineffective concentrations per se, PEA 10–
100 nM and luteolin 1 nM, they considerably decreased MC/9 cells
degranulation, suggesting a synergistic modulatory activity on
stimulated MCs (Fig. 3C). In line with the lower degranulation
observed, the PEA-luteolin combination signiﬁcantly reduced the
LDH release from activated MC/9 cells, a marker of cellular damage
(Fig. 3D).
2.4. The combination of PEA and luteolin reduces neurotoxicity
mediated by OGD-activated MC/9 cells
Next we determined if the synergistic effect exerted by PEA and
luteolin on MC/9 cells activation could limit the neurotoxic po-
tential of their CM. The drug association, luteolin 1 nM with PEA
100 nM, was added to the MC/9 cells 15 h before OGD exposureand maintained till 24 h after the OGD. The CM was then har-
vested and transferred to neurons. The relative LDH release in
control cells and in cells incubated with CM was 0.0670.01 and
0.3670.1 respectively (mean 7 SEM). The combination of PEA
and luteolin signiﬁcantly reduced the neurotoxic activity of CM
derived from MC/9 cells exposed to OGD (Fig. 4).
2.5. The combination of PEA and luteolin promotes synergistic neu-
roprotection in neurons exposed to OGD
To investigate whether PEA and luteolin were also endowed
with direct neuroprotective property, different concentrations of
the two molecules, alone or in association, were tested on neurons
previously exposed to 3 h of OGD. The drugs were added to the cell
cultures after the anoxic event and maintained in the recovery
medium for the following 24 h. In line with previous data (Lan-
zillotta et al., 2013, 2010; Sarnico et al., 2009), the relative LDH
release in control neurons and in neurons subjected to 3 h of OGD
was 0.170.02 and 0.3270.02 respectively (mean 7 SEM). PEA
did not exhibit signiﬁcant neuroprotective effect at any con-
centration tested in the range 10 pM 5 μM (Fig. 5A). Luteolin
showed a signiﬁcant neuroprotective activity at concentration
ranging from 100 nM to 1 μM, whereas it lost its effect at higher
concentrations (Fig. 5B). As observed in MC/9 cells, when the
drugs were administered together at per se ineffective or weakly
active concentrations, PEA 10–100 nM and luteolin 1 nM, they
signiﬁcantly reduced the neuronal cell death. This result suggests
Fig. 2. MC/9 cells activated by OGD release neurotoxic factors. (a) Image depicting the co-culture neurons-MC/9 cells system. Neurons are attached in the well, while MC/9
cells are plated in the upper trans-well. (b) Pure neurons or co-cultures neurons-MC/9 cells were challenged with 6 h of OGD, followed by 24 h of reperfusion. Toxicity was
determined by LDH release assay at the end of reperfusion period. The results are expressed as percentage of LDH released by pure neurons over basal value. Each value is
expressed as the mean 7 SEM of 9 wells from three independent experiments,**po0.01, t-test. (c) Neurons or MC/9 cells were seeded in equal volumes of medium at the
same densities employed in the previous experiment (250103 and 10103 cells/well, respectively). The cells were subjected to 6 h of OGD, followed by 24 h of reperfusion.
LDH release was measured at the end of the reperfusion period and expressed as percentage of the enzyme released by neurons exposed to OGD. The amount of LDH
released by mast cells was remarkably lower compared to the levels of the enzyme released by neurons. Each value is expressed as the mean 7 SEM of 6 wells from two
independent experiments,***po0.001, t-test. (d) Image depicting the conditioned medium (CM) protocol. MC/9 cells were maintained in anoxic conditions for 6 h. CM
collected immediately after OGD period, or after an additional 24 h of reperfusion, was transferred to neurons. After 24 h of incubation, toxicity was assessed by LDH release
assay. (e) Effect of CM derived from activated MC/9 cells on neurons. The results are expressed as percentage of LDH released by control neurons, i.e. non incubated with CM.
Supernatant obtained from OGD-activated MC/9 cells followed by additional 24 h of reperfusion induced signiﬁcant neurotoxicity. Each value is expressed as the mean 7
SEM of 9 wells from three independent experiments,***po0.001, one-way ANOVA followed by Dunnet's multiple comparison test.
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direct neuroprotective activity (Fig. 5C).3. Discussion
Our results show that OGD exposure induces degranulation of
the mastocytic MC/9 cells line. In accordance with previous ﬁnd-
ings, the amplitude of MCs degranulation is dependent on the
duration of anoxic insult (Hu et al., 2005). Degranulation was ac-
companied by signiﬁcant leakage of LDH, indicating a cytotoxic
effect induced by OGD. Active exocytic secretion and cytotoxic
release of cellular content are two types of mastocytic de-
granulation that can differently occur in response to speciﬁc exo-
genous stimuli or can be tuned by the stimulus intensity. For in-
stance, either linoleic or arachidonic acids can induce mastocytic
degranulation, although only linoleic acid induces a concomitant
LDH release (Masini et al., 1990). Eosinophil peroxidase at low
doses induces mastocytic degranulation, but at higher doses itpromotes both cytotoxic degranulation and LDH release (Hender-
son et al., 1980). Our experimental setting allowed to model the
injury produced by a severe brain ischemia on MCs resulting in
their cell damage and degranulation.
In neuron-MC/9 co-cultures subjected to OGD, the presence of
MCs exacerbated the neuronal cell death. A similar neurotoxic
effect was found when neurons were treated with supernatants
derived from MC/9 cells previously exposed to OGD. Worth of
note, only the CM collected after a recovery period following OGD,
and not the supernatant obtained immediately after OGD, was able
to induce massive neurotoxicity. A body of evidence shows that
MCs activation occurs in two phases (Silver and Curley, 2013;
Theoharides, 1990). The ﬁrst and rapid response occurs within
seconds after mastocytic activation and consists in the de-
granulation of MCs, i.e. the release of pre-formed mediators stored
in MCs granules. Granules contents include histamine, heparin,
serotonin, proteases, proteoglycans, cathepsin G and cytokines
(Nelissen et al., 2013; Silver and Curley, 2013). The second and
slow phase is the release of newly synthetized cytokines and
Fig. 3. Pre-treatment of MC/9 cells with the combination PEA-luteolin synergistically reduces OGD-dependent degranulation and LDH release. MC/9 cells were incubated
with PEA and luteolin, alone or in combination, or vehicle (DMSO) for 15 h before OGD and for the following 6 h of oxygen deprivation. After OGD the cells were processed to
determine their degranulation status by toluidine-blue staining and toxicity by LDH release assay. Values are expressed as percentage of degranulation or LDH release
determined in cells subjected to OGD over basal value. (a) Pre-treatment of MC/9 cells with PEA did not promote a signiﬁcant reduction of OGD-induced degranulation. Each
value is expressed as the mean 7 SEM of 9–18 wells from three-six independent experiments, p40.05, t-test. (b) Pre-treatment of MC/9 cells with luteolin at concentrations
10–100 nM was effective in preventing mastocytic degranulation. Each value is expressed as the mean 7 SEM of 6–18 wells from two-six independent experiments,
**po0.01 vs OGD þ vehicle, t-test. (c) While PEA at the concentrations 10 and 100 nM and luteolin 1 nM did not promote a signiﬁcant reduction of OGD-induced de-
granulation, the association of PEA and luteolin (PEA 10 nM þ luteolin 1 nM or PEA 100 nM þ luteolin 1 nM) considerably reduced MC/9 cells degranulation, suggesting a
synergistic action on stimulated MCs. Each value is expressed as the mean 7 SEM of 9 wells from three independent experiments,**po0.01, one-way ANOVA followed by
Dunnet's multiple comparison test. (d) Pre-treatment of MC/9 cells with the association of PEA and luteolin (PEA 100 nM þ luteolin 1 nM) signiﬁcantly reduced OGD-
induced toxicity. Each value is expressed as the mean 7 SEM of 9 wells from three independent experiments,*po0.005, t-test.
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tivation (Nelissen et al., 2013; Silver and Curley, 2013). The mole-
cules released in the different phases of mastocytic activation can
promote and modulate the organism reaction to exogenous sti-
muli, inducing inﬂammatory processes such as the recruitment
and the activation of inﬂammatory cells, vasodilation and plasma
extravasation, but can also drive anti-inﬂammatory or im-
munosuppressive responses (Christy and Brown, 2007; Galli et al.,
2005; Marshall, 2004; Metz et al., 2007; Silver and Curley, 2013).
Our results suggest that under severe ischemia MCs can release
neurotoxic factors that are mainly synthetized ex novo in the post-
anoxia period.
Our experiments demonstrate that PEA per se was inactive in
reducing either MC/9 cells activation or neuronal cell death when
the cell cultures were exposed to OGD. By contrast, luteolin was
able to decrease mastocytic activation at the concentration range
10–100 nM and neuronal cell death at the 100 nM- 1 μM range.
The effects promoted by luteolin on MCs and neurons disappeared
at higher concentrations. Multiple factors could account for this
phenomenon, including a possible pro-oxidant activity of the
molecule at higher doses (Lin et al., 2008). Future studies are
needed to determine the mechanism behind the loss ofneuroprotective activity of luteolin.
The combination of the molecules PEA: luteolin 10:1 or 100:1
at the nanomolar range maximally reduced the degranulation and
LDH release from MCs and induced neuroprotection in nearly pure
cortical neurons exposed to OGD. Notably, in primary neurons the
drug combination was effective when added after the OGD ex-
posure. Either in neurons or in MCs the effective combination was
obtained using the compounds at concentrations per se inactive.
This evidence strongly suggests the synergistic activity of the two
drugs in producing an overall neuroprotection in models of brain
ischemia. The synergistic action of PEA and luteolin is relevant also
in the light of the severe anoxic conditions employed in this study,
that can reasonably mimic the environment encountered by MCs
in the core region of the ischemic brain.
The mechanism by which PEA-luteolin association can promote
neuroprotection in MCs/neurons system subjected to anoxic insult
remains to be explored yet. Previous studies have shown that PEA-
luteolin combination can reduce inﬂammatory processes asso-
ciated with spinal cord injury and TBI by restoring basal expres-
sions of peroxisome proliferator-activated receptors (PPARs) and
by limiting nuclear factor-kB (NF-kB) activation (Cordaro et al.,
2015; Paterniti et al., 2013). Moreover, PEA-luteolin association
Fig. 4. The combination PEA-luteolin reduces the neurotoxicity mediated by OGD-
activated MC/9 cells. MC/9 cells were treated with the vehicle or the association of
PEA and luteolin (PEA 100 nM þ luteolin 1 nM) for 15 h before OGD. The incuba-
tion with the vehicle (DMSO) or the drugs was carried on for the 6 h of OGD and
the following 24 h of reperfusion. CM obtained as previously described was used to
incubate cortical neurons for 24 h, at the end of which the cellular damage was
assessed by LDH release assay. Results are expressed as percentage of LDH released
by neurons incubated with CM from MC/9 cells subjected to OGD over basal value.
The combination PEA-luteolin signiﬁcantly reduced the neurotoxicity mediated by
OGD-activated MCs. Each value is expressed as the mean 7 SEM of 6 wells from
two independent experiments,*po0.05, t-test.
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models of TBI and arthritis (Cordaro et al., 2015; Impellizzeri et al.,
2013). Notably, both TNF-α and IL-1β, known to induce direct
neurotoxicity, can be released by activated MCs (Galli et al., 2005;
Silver and Curley, 2013). These classical factors released during
neurotoxic activation of MCs, and possibly other yet unidentiﬁed
molecules, deserve further investigation.
A number of clinical studies conﬁrmed the anti-inﬂammatory
and analgesic properties of PEA, while basically no adverse effects
were observed at pharmacological doses (Skaper et al., 2014). Few
clinical studies exist for luteolin, but none of them reported major
side effects (Taliou et al., 2013; Theoharides et al., 2012). Im-
portantly, PEA and luteolin are natural products present in many
foods. PEA is a food component of egg yolk, peanut oil and soybean
lecithin (Esposito and Cuzzocrea, 2013). Consumption of these
foods has been associated to anti-allergic and anti-inﬂammatory
activities in laboratory animals and to a decrease of rheumatic
fever in children, likely via PEA activity (Esposito and Cuzzocrea,
2013). Luteolin and its glycosides are widely distributed in the
plant kingdom and have been identiﬁed in many edible plants
(Lopez-Lazaro, 2009) (for a complete list, see “USDA database for
the ﬂavonoid content of selected foods”). Different studies indicate
that luteolin can be absorbed after oral administration and that its
bioavailability and metabolism are sufﬁcient to allow it to exert its
biological activities in vivo (Lopez-Lazaro, 2009).The effect promoted by the pre-treatment with PEA-luteolin on
OGD-activated MCs would suggest a possible clinical application of
the drug combination in the prevention of stroke, for instance, in
association with antithrombotic and antihypertensive agents. In
this study we did not explore the effects of the drugs when added
to MCs just after the OGD exposure, though we showed that MCs
can release neurotoxic factors synthetized ex novo in the post-OGD
period and that PEA-luteolin can limit the cell death when added
to cultured neurons after the OGD. These ﬁndings, together with
the evidence that PEA-luteolin are neuroprotective when ad-
ministered to rats after the onset of brain ischemia (Caltagirone
et al., 2015), raise the possibility that the drug combination may be
of therapeutical value even when administered in the acute post
ischemic phase.4. Conclusions
Here we present a novel cell-based model to study the role of
MCs in brain ischemia. The use of MC/9 cells and the co-culture
system neurons-MC/9 cells under OGD conditions allowed us to
analyze the response of MCs to ischemic stimuli and to evaluate
the contribution of MCs in anoxia-induced neurotoxicity. More-
over, we demonstrated that the combination of the two natural
compounds, PEA and luteolin, at very low concentrations, elicits a
synergistic modulation of MCs-mediated neurotoxicity beside a
direct neuroprotection of primary neurons. Future studies are
needed to further elucidate the mechanism underlying the sy-
nergy of the PEA-luteolin association.5. Experimental procedures
5.1. Drugs
PEA and luteolin were provided by Epitech Group s.r.l., Sacco-
longo, Italy. The compounds were dissolved in dimethyl sulfoxide
(DMSO, Sigma-Aldrich, Saint Louis, MO, U. S. A.). DMSO was used
at a ﬁnal dilution lower than 1%, a concentration that we found
having no effect on MCs and neurons in our experimental condi-
tions (data not shown).
5.2. Cell cultures
5.2.1. Primary cultures of mouse cortical neurons
Primary cultures of mouse cortical neurons derived from
C57BL/6 mice (Charles River Italia, Calco, Italy). All animal studies
were approved by the Animal Research Committees of the Uni-
versity of Brescia and follow the Directive 2010/63/EU of the
European Parliament and of the Council of 22 September 2010 on
the protection of animals used for scientiﬁc purposes. The neurons
were obtained from cortices of 15-day embryonic mice as pre-
viously described (Lanzillotta et al., 2013). The cells were seeded at
the density 2.5105 cells/well in 24-well plates (Nunc-Thermo
Scientiﬁc, Waltham, MA, U.S.A.) coated with 10 μg/mL poly-l-ly-
sine (Sigma-Aldrich, Saint Louis, MO, U.S.A.) using Neurobasal
medium (Invitrogen Corporation, Carlsbad, CA, USA) supple-
mented with 2% B27 (Invitrogen Corporation), 0.5 mM l-glutamine
(Euroclone, Celbio spa, Milan, Italy) and 50 U/mL penicillin/strep-
tomicin (Euroclone). The neurons were used after 11–12 days in
vitro (DIV).
5.2.2. MC/9 cells
MC/9 cells are cloned MCs derived from mouse fetal liver
(ATCC, Rockville, MD, U. S. A.). The cell line was cultured in ap-
propriate growth medium (High glucose Dulbecco’s Modiﬁed
Fig. 5. The combination PEA-luteolin promotes synergistic neuroprotection in neurons subjected to OGD. Cortical neurons were subjected to 3 h of OGD as previously
described. After OGD the cells were treated with vehicle (DMSO) or different concentrations of PEA and luteolin alone or in combination as indicated. After 24 h of
reperfusion LDH release was measured. Values are expressed as percentage of LDH released by neurons exposed to OGD over basal value. (a) PEA was not effective in
promoting a signiﬁcant neuroprotection in any of the considered concentrations. Each value is expressed as the mean 7 SEM of 6–12 wells from two-four independent
experiments. p40.05, t-test. (b) Luteolin exhibited a signiﬁcant neuroprotective activity at the concentrations ranging from 100 nM to 1 μM. Each value is expressed as the
mean 7 SEM of 9 wells from three independent experiments. **po0.01,***po0.001, t-test. (c) When tested in association at the nanomolar ratio 10:1 and 100:1 (PEA:
luteolin), the two molecules promoted a massive neuroprotective effect higher than the effect induced by the single compounds, suggesting a synergy of the association.
Each value is expressed as the mean 7 SEM of 9 wells from three independent experiments,**po0.01,***po0.001, one-way ANOVA followed by Dunnet's multiple
comparison test.
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mine and 10% fetal bovine serum -Euroclone-, 0.05 mM 2-mer-
captoethanol –Sigma-Aldrich-, 10% Rat T-STIM -Becton Dickinson,
San Jose, CA, USA-) according to producer's speciﬁcations. MC/9
cells were cultured in suspension and maintained by the addition
of fresh medium or its replacement. The cells were plated in 96-
well plates (Costar Corning Incorporate, NY, USA) at the density
6104 cells/well for toluidine blue staining, in 24-well plates
(Costar Corning Incorporate) at the density 5105 cells/well for β-
hexosaminidase release assay and viability studies.
5.3. OGD
Oxygen glucose deprivation (OGD) was performed in cortical
neurons, MC/9 cells or co-cultures neurons-MC/9 as previously
described (Lanzillotta et al., 2013). Brieﬂy, cells were incubated
with warm deoxygenated glucose-free balanced salt solution
[(containing in mM): 5.36 KCl, 116.35 NaCl, 0.81 MgSO4 and 1.01
NaH2PO4)] and transferred to an air-tight chamber ﬂuxed with an
anaerobic gas mixture (95% N2 and 5% CO2) for 10 min to remove
oxygen. The oxygen concentration was o0.4% throughout theOGD period, as assessed by an oxygen analyzer (Servomex 580 A,
Taylor Servomex, Edenbridge, UK). Cells were exposed to OGD at
37 °C for the indicated amount of time. Control cell cultures were
incubated in a normal aerated incubator for the same time period.
At the end of the OGD cells were allowed to recover in Neurobasal
medium containing 0.4% B27 under normoxic conditions. In the
experiments exploring MCs activation (pure MC/9 cells, or in co-
cultures with neurons), at the end of OGD, supplements (glucose,
L-glutamine, penicillin/streptomycin and B27) were added directly
to the glucose-free balanced salt solution in order to limit mas-
tocytic activation derived from mechanical manipulation.
Cell lines were treated with PEA and luteolin, alone or in
combination, before or after OGD, as described. The cell viability
was estimated 24 h later for neurons and neurons-MC/9 co-cul-
tures, or as speciﬁcally indicated for MC/9 cells. Mastocytic de-
granulation was assessed at the end of the OGD exposure.
5.4. Interaction neurons-mast cells
5.4.1. Co-cultures neurons-MC/9 cells
Cortical neuron cultures were plated in coated 24-well plates at
E. Parrella et al. / Brain Research 1648 (2016) 409–417416the density 2.5105 cells/well (Nunc-Thermo Scientiﬁc) as de-
scribed above. MC/9 cells were plated in 6.5 mm diameter cell
culture inserts (polyethylene terephthalate membrane, pore size
0.4 mm; Merck Millipore Billerica, MA, USA) at 10103 cells per
insert, and placed into the culture wells containing neurons fol-
lowing the manufacturer instructions (Fig. 2A).
5.4.2. Preparation of MC/9-conditioned medium (CM)
In a different experimental approach, neurons were incubated
in CM derived from MC/9 cells subjected to OGD (Fig. 2D). MC/9
cells were plated at the density 7105 cells/well in 60 mm dia-
meter Petri dishes (Costar Corning Incorporate) and subjected to
OGD as previously described. At the end of OGD period alone or at
the end of OGD followed by incubation in recovery medium, su-
pernatants were collected, samples were sedimented to remove
MC/9 cells and particulates, and 500 μL of CM were transferred to
the neurons plated in 24-well plates (Nunc-Thermo Scientiﬁc).
5.5. Degranulation assessment
5.5.1. Toluidine blue staining
MCs abundant cytoplasmic granules can be purple stained
using metachromatic dye such as toluidine blue. MC/9 cells were
ﬁxed with Immunoﬁx (Bio-Optica, Milano, Italy) and stained with
0.005% toluidine blue pH 2.5 (Merck, Darmstadt, Germany). The
number of degranulated MCs was counted under a light micro-
scope, considering degranulated the cells showing lack of cellular
periphery integrity, pale purple staining or extrusion of granules
out of the cells (Hu et al., 2005). The numbers of degranulated and
total MCs were assessed from three randomly selected areas
counting a minimum of 300 cells/ﬁeld. The results were expressed
as the degranulation percentage in each well.
5.5.2. β-hexosaminidase release assay
Degranulation was also evaluated measuring the exocytosis of
β-hexosaminidase, an enzyme released from secretory granules of
activated MCs. The protocol used is based on the method de-
scribed by Kawahara (Kawahara, 2012). Brieﬂy, 40 μL of MCs su-
pernatant was transferred to a 96-well microtiter plate (Greiner
Bio-One, Frickenhausen, Germany) and incubated with 40 μL of
1 mM p-nitrophenyl-N-acetyl-d-glucosaminide (Sigma-Aldrich) in
0.1 M citrate buffer (pH 4.5) for 1 h at 37 °C. The reaction was
stopped by adding 160 μL of 0.1 M carbonate buffer (pH 10.0). The
total β-hexosaminidase value was estimated by lysing the cells
with 0.1% Triton-X 100. The absorbance of the mixture was mea-
sured at 405 nm using a microplate reader (iMark; Bio-Rad, Her-
cules, CA, USA). The relative value of the β-hexosaminidase activity
was calculated as percentage of β-hexosaminidase released/β-
hexosaminidase total.
5.6. Cytotoxicity assessment
Neuronal and mastocytic injuries were evaluated by measuring
the amount of lactate dehydrogenase (LDH) released into the
culture medium using the CytoTox 96s Non-Radioactive Cyto-
toxicity Assay (Promega Corporation, Wisconsin, USA) according to
the manufacturer's instructions. In each well, LDH release was
calculated relative to total releasable LDH obtained by incubating
the cells for 30 min with 1% Triton X-100 at the end of each ex-
periment. Values are expressed as a percentage of LDH released by
cells exposed to OGD or CM over basal value.
5.7. Statistical analysis
All results were expressed as mean7SEM (standard error of
the mean). Student’s t-test and one-way ANOVA followed byDunnet's multiple comparison test were used for comparison of
two or more than two groups, respectively. Po0.05 was con-
sidered statistically signiﬁcant.Competing interests
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